<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Curr Glaucoma Pract</journal-id><journal-id journal-id-type="iso-abbrev">J Curr Glaucoma Pract</journal-id><journal-id journal-id-type="publisher-id">JOCGP</journal-id><journal-title-group><journal-title>Journal of Current Glaucoma Practice</journal-title></journal-title-group><issn pub-type="ppub">0974-0333</issn><issn pub-type="epub">0975-1947</issn><publisher><publisher-name>Jaypee Brothers Medical Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9385390</article-id><article-id pub-id-type="doi">10.5005/jp-journals-10078-1350</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Factors Associated with 5-year Glaucomatous Progression in Glaucoma Suspect Eyes: A Retrospective Longitudinal Study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nassiri</surname><given-names>Nariman</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Shibandri</given-names></name><xref rid="aff1" ref-type="aff">2</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8327-9227</contrib-id></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Vaama</given-names></name><xref rid="aff1" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Nirmalan</surname><given-names>Aravindh</given-names></name><xref rid="aff2" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Patwa</surname><given-names>Dhir</given-names></name><xref rid="aff1" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Heriford</surname><given-names>Alexandra</given-names></name><xref rid="aff3" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Chaesik</given-names></name><xref rid="aff1" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Haoxing</given-names></name><xref rid="aff1" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Ridha</surname><given-names>Faisal</given-names></name><xref rid="aff1" ref-type="aff">9</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3983-2854</contrib-id></contrib><contrib contrib-type="author"><name><surname>Tannir</surname><given-names>Justin</given-names></name><xref rid="aff4" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Goyal</surname><given-names>Anju</given-names></name><xref rid="aff1" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name><surname>Juzych</surname><given-names>Mark S</given-names></name><xref rid="aff1" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>Bret A</given-names></name><xref rid="aff1" ref-type="aff">13</xref></contrib></contrib-group><aff id="aff1">
<label>1-3,5,7-9,11-13</label> Ophthalmology, Kresge Eye Institute, Wayne State University School of Medicine, Detroit, Michigan, United States</aff><aff id="aff2">
<label>4</label> Wayne State University School of Medicine, Detroit, Michigan, United States</aff><aff id="aff3">
<label>6</label> Michigan State University, College of Osteopathic Medicine, East Lansing, Michigan, United States</aff><aff id="aff4">
<label>10</label> John D. Dingell VA Medical Center, Wayne State University School of Medicine, Detroit, Michigan, United States</aff><author-notes><corresp id="cor1">Nariman Nassiri, 4717 St. Antoine, Detroit, Michigan, United States, Phone: +1-773-344-6602, e-mail: <email>nassiri.nariman@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Apr</season><year>2022</year></pub-date><volume>16</volume><issue>1</issue><fpage>11</fpage><lpage>16</lpage><permissions><copyright-statement>Copyright &#x000a9; 2022; The Author(s).</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>&#x000a9; The Author(s). 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract><title>A<sc>bstract</sc></title><sec><title>Purpose</title><p>Using demographic, clinical, visual field, and optical coherence tomography (OCT) variables to study the association of 5-year glaucomatous progression in glaucoma suspect eyes.</p></sec><sec><title>Patients and methods</title><p>This is a retrospective longitudinal clinical study. Inclusion criteria consisted of glaucoma suspect eyes (i.e., concerning cup-to-disk ratio and/or intraocular pressure (IOP) &#x0003e;21 mm Hg), age &#x02265; 30 years old, follow-up time of 5 years, best-corrected visual acuity (BCVA) of 20/100 or better, spherical equivalent (SE) higher than 8 diopters and an astigmatism less than 3 diopters. Eyes with glaucoma&#x02014;determined by two consecutive, reliable visual field tests&#x02014;were excluded, as well as any eyes with any clinically significant retinal or neurological disease. The percentage of glaucoma suspect eyes, which progressed to glaucoma within a 5-year period, was calculated. Study subjects were divided into the following groups: eyes that progressed to glaucoma and those that did not.</p></sec><sec><title>Results</title><p>In the 288 patients which we looked at, 365 total eyes, 323 eyes had concerning cup-to-disk ratio and 42 had ocular hypertension. Bivariate analysis showed that the eyes which progressed to glaucoma had significantly worse mean deviation, increased pattern standard deviation (PSD), and less visual field index (VFI). Our bivariate analysis also showed a thinner average, superior and inferior retinal nerve fiber layer thickness (RNFL), and more severe average, superior, and inferior RNFL damages (i.e., color grading scale) at baseline. Logistic regression analysis showed that only PSD and severe inferior RNFL damage (i.e., red color) to be significantly associated with 5-year glaucomatous progression.</p></sec><sec><title>Conclusion</title><p>Segmental RNFL damage and pattern standard deviation are associated with 5-year glaucomatous progression in glaucoma suspect eyes.</p></sec><sec><title>How to cite this article</title><p>Nassiri N, Das S, Patel V, <italic>et al.</italic> Factors Associated with 5-year Glaucomatous Progression in Glaucoma Suspect Eyes: A Retrospective Longitudinal Study. J Curr Glaucoma Pract 2022;16(1):11-16.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Glaucomatous progression</kwd><kwd>Glaucoma suspect</kwd><kwd>Ocular hypertension</kwd><kwd>Optical coherence tomography (OCT)</kwd><kwd>Retinal nerve fiber layer (RNFL)</kwd><kwd>Risk factors</kwd><kwd>Visual field index</kwd><kwd>Visual field</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>I<sc>ntroduction</sc></title><p>Glaucoma is a multifactorial progressive optic neuropathy, characterized by advanced neurodegeneration of the eye's retinal ganglion cells (RGCs) and their axons. This is determined by retinal nerve fiber layer (RNFL) attenuation, a specific pattern of damage to the optic nerve head, and visual field loss.<sup><xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref></sup> Different studies have shown that the development of glaucoma is correlated with several factors such as age,<sup><xref rid="B1" ref-type="bibr">1</xref></sup> glaucoma in one's family,<sup><xref rid="B2" ref-type="bibr">2</xref></sup> microvascular diseases (e.g., diabetes and hypertension),<sup><xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref></sup> vasospastic conditions (e.g., migraine),<sup><xref rid="B5" ref-type="bibr">5</xref></sup> myopia,<sup><xref rid="B6" ref-type="bibr">6</xref></sup> intraocular pressure (IOP),<sup><xref rid="B1" ref-type="bibr">1</xref></sup> and severity of visual field loss at diagnosis.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Improving our knowledge about factors that are associated with glaucomatous changes is crucial for earlier diagnosis of glaucoma. The significant factor in delaying vision loss due to glaucoma is its early diagnosis and treatment.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> The United States Preventive Services Task Force (USPSTF) found insufficient evidence on the advantages of early glaucoma screening. However, the USPSTF did find evidence that treatment of IOP and early glaucoma lessens the number of individuals who develop small, clinically unnoticeable visual field defects. Meanwhile, there was evidence that the management of early asymptomatic primary open angle glaucoma reduces the number of individuals who experienced worsening visual field defects.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p><p>In this study, we investigated the association of 5-year glaucomatous progression with several demographic, clinical, visual field, and optical coherence tomography (OCT) variables in glaucoma suspect eyes. Currently, there is limited data on using OCT parameters in the prediction of glaucomatous progression.</p></sec><sec sec-type="methods"><title>M<sc>ethods</sc></title><sec><title>Study Subjects</title><p>This 5-year retrospective study was performed at an inner city, tertiary care center and was approved by the Institutional Review Board at Wayne State University. Eyes who met the eligibility criteria were included in our study. Inclusion criteria were as follows: glaucoma suspect eyes defined as a concerning cup-to-disk ratio and/or intraocular pressure &#x0003e;21 mm Hg, age &#x02265;30 years old, follow-up time of 5 years, best corrected visual acuity (BCVA) of 20/100 or better, spherical equivalent (SE) better than &#x02212;8 diopters (D), and an astigmatism less than 3D. Eyes with glaucoma which were determined by at least two consecutive reliable visual field test results (24&#x02013;2 Swedish Interactive Thresholding Algorithm [SITA] strategy, SITA&#x02013;Fast; Humphrey Field Analyzer) and/or a pattern standard deviation (PSD) with <italic>p</italic>-value less than 0.05 were excluded. Our exclusion criteria strictly followed this definition, regardless of the appearance of the optic disk.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> Furthermore, eyes with any significant retinal or neurological abnormalities were excluded. If both eyes of the same patient were eligible, both were included.</p></sec><sec><title>Study Outcomes</title><p>Glaucoma suspect eyes were divided into two groups; those which progressed to glaucoma vs those which did not (over 5-year follow-up). <xref rid="T1" ref-type="table">Table 1</xref> shows the demographic, clinical, visual field and optical coherence tomography (OCT) characteristics of eyes included in our study. Visual field reliability was defined according to the manufacturer's criteria as fixation loss &#x0003c;20%, false-positive errors &#x0003c;15%, and false-negative errors &#x0003c;15%. We used quality Cirrus OCT scans, defined as scans with signal strength &#x0003e;6, and without any retinal nerve fiber layer (RNFL) diskontinuity, misalignment, involuntary saccade, or blinking artifacts. The OCT scans were within 6 months of the visual field tests. We calculated the percentage of glaucoma suspect eyes that progressed to glaucoma within a 5-year time period.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Demographic and baseline characteristics of study populations</p></caption><table frame="hsides" rules="groups" cellpadding="10" cellspacing="0"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Total</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Progressed to glaucoma</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Not progressed to glaucoma</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p-value</italic>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Number of eyes, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">365</td><td align="center" valign="top" rowspan="1" colspan="1">55 (15.07)</td><td align="center" valign="top" rowspan="1" colspan="1">310 (84.93)</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Number of patients, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">288</td><td align="center" valign="top" rowspan="1" colspan="1">50 (17.36)</td><td align="center" valign="top" rowspan="1" colspan="1">238 (82.63)</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Female: Male, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">288</td><td align="center" valign="top" rowspan="1" colspan="1">28 (56): 22 (44)</td><td align="center" valign="top" rowspan="1" colspan="1">157 (66): 81 (34)</td><td align="center" valign="top" rowspan="1" colspan="1">0.24<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Race, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">African-American</td><td align="center" valign="top" rowspan="1" colspan="1">240 (83.33)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (82.00)</td><td align="center" valign="top" rowspan="1" colspan="1">199 (83.61)</td><td rowspan="3" align="center" valign="top" colspan="1">0.44<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Caucasian</td><td align="center" valign="top" rowspan="1" colspan="1">37 (12.85)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (12.00)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (11.34)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other*</td><td align="center" valign="top" rowspan="1" colspan="1">11 (3.82)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (6.00)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (5.04)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Right: Left, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">365</td><td align="center" valign="top" rowspan="1" colspan="1">28 (51): 27 (49)</td><td align="center" valign="top" rowspan="1" colspan="1">167 (54): 143 (46)</td><td align="center" valign="top" rowspan="1" colspan="1">0.80<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Age (years), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">59.08 &#x000b1; 11.24</td><td align="center" valign="top" rowspan="1" colspan="1">59.08 &#x000b1; 11.24</td><td align="center" valign="top" rowspan="1" colspan="1">56.87 &#x000b1; 11.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Blood hypertension, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">204 (70.83)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (82.00)</td><td align="center" valign="top" rowspan="1" colspan="1">163 (68.49)</td><td rowspan="2" align="center" valign="top" colspan="1">0.08<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">84 (29.17)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (18.00)</td><td align="center" valign="top" rowspan="1" colspan="1">75 (31.51)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Diabetes mellitus, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">96 (32.98)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (40.00)</td><td align="center" valign="top" rowspan="1" colspan="1">76 (31.93)</td><td rowspan="2" align="center" valign="top" colspan="1">0.32<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">192 (67.02)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (60.00)</td><td align="center" valign="top" rowspan="1" colspan="1">162 (68.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Family history of glaucoma, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">126 (43.75)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (46.00)</td><td align="center" valign="top" rowspan="1" colspan="1">103 (43.28)</td><td rowspan="2" align="center" valign="top" colspan="1">0.84<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">162 (56.25)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (54.00)</td><td align="center" valign="top" rowspan="1" colspan="1">135 (56.72)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Fellow eye diagnosed with glaucoma, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">34 (9.32)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (18.18)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (7.74)</td><td rowspan="2" align="center" valign="top" colspan="1">0.15<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">331 (90.68)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (81.82)</td><td align="center" valign="top" rowspan="1" colspan="1">286 (92.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Lens status (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phakic</td><td align="center" valign="top" rowspan="1" colspan="1">257 (70.41)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (70.91)</td><td align="center" valign="top" rowspan="1" colspan="1">218 (70.32)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pseudophakic</td><td align="center" valign="top" rowspan="1" colspan="1">108 (29.59)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (29.09)</td><td align="center" valign="top" rowspan="1" colspan="1">92 (29.68)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Time converted to glaucoma from baseline (months), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">19.12 &#x000b1; 4.23</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>BCVA, LogMAR, mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.083 &#x000b1; 0.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.084 &#x000b1; 0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.083 &#x000b1; 0.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.98<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>IOP (mm Hg), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">18.07 &#x000b1; 3.64</td><td align="center" valign="top" rowspan="1" colspan="1">18.07 &#x000b1; 3.64</td><td align="center" valign="top" rowspan="1" colspan="1">17.24 &#x000b1; 3.80</td><td align="center" valign="top" rowspan="1" colspan="1">0.13<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>No. of eyes on medication (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">48 (13.15)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (12.73)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (13.23)</td><td rowspan="2" align="center" valign="top" colspan="1">0.70<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">317 (86.85)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (87.27)</td><td align="center" valign="top" rowspan="1" colspan="1">269 (86.77)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>No. IOP-lowering Medications</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.54 &#x000b1; 0.63</td><td align="center" valign="top" rowspan="1" colspan="1">0.47 &#x000b1; 0.59</td><td align="center" valign="top" rowspan="1" colspan="1">0.54 &#x000b1; 0.58</td><td align="center" valign="top" rowspan="1" colspan="1">0.09<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>CCT (microns), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">540.25 &#x000b1; 47.12</td><td align="center" valign="top" rowspan="1" colspan="1">538.51 &#x000b1; 52.10</td><td align="center" valign="top" rowspan="1" colspan="1">542.20 &#x000b1; 43.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.97<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>MD (dB), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">-0.99 &#x000b1; 1.59</td><td align="center" valign="top" rowspan="1" colspan="1">-1.46 &#x000b1; 2.02</td><td align="center" valign="top" rowspan="1" colspan="1">-0.91 &#x000b1; 1.49</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.02</bold>
<xref rid="TFN1-2" ref-type="table-fn">
<sup>++</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>MD (dB) &#x02264; &#x02212;1dB, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">148 (40.55)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (50.91)</td><td align="center" valign="top" rowspan="1" colspan="1">120 (38.71)</td><td rowspan="2" align="center" valign="top" colspan="1">0.12<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">217 (59.45)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (49.09)</td><td align="center" valign="top" rowspan="1" colspan="1">190 (61.29)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>PSD, mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.42 &#x000b1; 0.20</td><td align="center" valign="top" rowspan="1" colspan="1">1.50 &#x000b1; 0.21</td><td align="center" valign="top" rowspan="1" colspan="1">1.40 &#x000b1; 0.20</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;0.01</bold>
<xref rid="TFN1-2" ref-type="table-fn">
<sup>++</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>VFI, mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">99.06 &#x000b1; 1.00</td><td align="center" valign="top" rowspan="1" colspan="1">98.71 &#x000b1; 1.20</td><td align="center" valign="top" rowspan="1" colspan="1">99.12 &#x000b1; 0.95</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;0.01</bold>
<xref rid="TFN1-2" ref-type="table-fn">
<sup>++</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Vertical C/D ratio, mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.60 &#x000b1; 0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.61 &#x000b1; 0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.60 &#x000b1; 0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.59<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>C/D asymmetry, mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.10 &#x000b1; 0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.11 &#x000b1; 0.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.10 &#x000b1; 0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.70<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Average RNFL thickness (micron), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">86.73 &#x000b1; 11.72</td><td align="center" valign="top" rowspan="1" colspan="1">83.39 &#x000b1; 14.41</td><td align="center" valign="top" rowspan="1" colspan="1">88.34 &#x000b1; 9.98</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;0.01</bold>
<xref rid="TFN1-2" ref-type="table-fn">
<sup>++</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Inferior RNFL thickness (micron), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">112.67 &#x000b1; 17.82</td><td align="center" valign="top" rowspan="1" colspan="1">105.67 &#x000b1; 22.66</td><td align="center" valign="top" rowspan="1" colspan="1">114.54 &#x000b1; 16.52</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;0.01</bold>
<xref rid="TFN1-2" ref-type="table-fn">
<sup>++</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Nasal RNFL thickness (micron), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">68.67 &#x000b1; 13.11</td><td align="center" valign="top" rowspan="1" colspan="1">67.65&#x000b1; 14.48</td><td align="center" valign="top" rowspan="1" colspan="1">69.59 &#x000b1; 12.86</td><td align="center" valign="top" rowspan="1" colspan="1">0.32<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Superior RNFL thickness (micron), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">108.42 &#x000b1; 20.27</td><td align="center" valign="top" rowspan="1" colspan="1">103.11 &#x000b1; 25.84</td><td align="center" valign="top" rowspan="1" colspan="1">110.74 &#x000b1; 16.77</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x0003c;0.01</bold>
<xref rid="TFN1-2" ref-type="table-fn">
<sup>++</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Temporal RNFL thickness (micron), mean &#x000b1; SD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">57.50 &#x000b1; 11.47</td><td align="center" valign="top" rowspan="1" colspan="1">56.65 &#x000b1; 12.30</td><td align="center" valign="top" rowspan="1" colspan="1">58.17 &#x000b1; 10.54</td><td align="center" valign="top" rowspan="1" colspan="1">0.34<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Cup volume (mm</bold>3<bold>), mean &#x000b1; SD</bold></td><td align="center" valign="top" rowspan="1" colspan="1">0.33 &#x000b1; 0.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.33 &#x000b1; 0.26</td><td align="center" valign="top" rowspan="1" colspan="1">0.33 &#x000b1; 0.22</td><td align="center" valign="top" rowspan="1" colspan="1">0.92<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Disk area (mm</bold>2<bold>), mean &#x000b1; SD</bold></td><td align="center" valign="top" rowspan="1" colspan="1">2.07 &#x000b1; 0.41</td><td align="center" valign="top" rowspan="1" colspan="1">2.10 &#x000b1; 0.45</td><td align="center" valign="top" rowspan="1" colspan="1">2.05 &#x000b1; 0.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.45<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Rim area (mm</bold>2<bold>), mean &#x000b1; SD</bold></td><td align="center" valign="top" rowspan="1" colspan="1">1.20 &#x000b1; 0.27</td><td align="center" valign="top" rowspan="1" colspan="1">1.20 &#x000b1; 0.34</td><td align="center" valign="top" rowspan="1" colspan="1">1.20 &#x000b1; 0.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.96<xref rid="TFN1-2" ref-type="table-fn"><sup>++</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Average RNFL color, n (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">18 (4.93)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (7.27)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (4.52)</td><td rowspan="4" align="center" valign="top" colspan="1">
<bold>&#x0003c;0.01</bold>
<xref rid="TFN1-1" ref-type="table-fn">
<sup>+</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Green</td><td align="center" valign="top" rowspan="1" colspan="1">285 (78.08)</td><td align="center" valign="top" rowspan="1" colspan="1">37 (67.27)</td><td align="center" valign="top" rowspan="1" colspan="1">248 (80.00)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yellow</td><td align="center" valign="top" rowspan="1" colspan="1">49 (13.42)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (12.73)</td><td align="center" valign="top" rowspan="1" colspan="1">42 (13.55)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Red</td><td align="center" valign="top" rowspan="1" colspan="1">13 (3.56)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (12.73)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (1.93)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Inferior RNFL color, n (%)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">17 (4.66)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.85)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (4.61)</td><td rowspan="4" align="center" valign="top" colspan="1">
<bold>&#x0003c;0.01</bold>
<xref rid="TFN1-1" ref-type="table-fn">
<sup>+</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Green</td><td align="center" valign="top" rowspan="1" colspan="1">295 (80.82)</td><td align="center" valign="top" rowspan="1" colspan="1">37 (72.22)</td><td align="center" valign="top" rowspan="1" colspan="1">258 (83.88)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yellow</td><td align="center" valign="top" rowspan="1" colspan="1">31 (8.49)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (5.56)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (8.22)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Red</td><td align="center" valign="top" rowspan="1" colspan="1">22 (6.03)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (20.37)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (3.30)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Nasal RNFL color, n (%)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">25 (6.85)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (7.27)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (6.77)</td><td rowspan="4" align="center" valign="top" colspan="1">0.52<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Green</td><td align="center" valign="top" rowspan="1" colspan="1">323 (89.31)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (87.27)</td><td align="center" valign="top" rowspan="1" colspan="1">275 (88.71)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yellow</td><td align="center" valign="top" rowspan="1" colspan="1">11 (3.01)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.82)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (3.23)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Red</td><td align="center" valign="top" rowspan="1" colspan="1">6 (1.64)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.64)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1.29)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Superior RNFL color, n (%)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">21 (5.75)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (10.91)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (4.84)</td><td rowspan="4" align="center" valign="top" colspan="1">
<bold>&#x0003c;0.01</bold>
<xref rid="TFN1-1" ref-type="table-fn">
<sup>+</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Green</td><td align="center" valign="top" rowspan="1" colspan="1">290 (79.45)</td><td align="center" valign="top" rowspan="1" colspan="1">33 (60.00)</td><td align="center" valign="top" rowspan="1" colspan="1">257 (82.90)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yellow</td><td align="center" valign="top" rowspan="1" colspan="1">25 (6.85)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (10.91)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (6.13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Red</td><td align="center" valign="top" rowspan="1" colspan="1">29 (7.94)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (18.18)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (6.13)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Temporal RNFL color, n (%)</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">10 (2.74)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.64)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (2.58)</td><td rowspan="4" align="center" valign="top" colspan="1">0.31<xref rid="TFN1-1" ref-type="table-fn"><sup>+</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Green</td><td align="center" valign="top" rowspan="1" colspan="1">305 (83.56)</td><td align="center" valign="top" rowspan="1" colspan="1">42 (76.36)</td><td align="center" valign="top" rowspan="1" colspan="1">263 (84.83)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yellow</td><td align="center" valign="top" rowspan="1" colspan="1">28 (7.67)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (10.91)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (7.10)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Red</td><td align="center" valign="top" rowspan="1" colspan="1">22 (6.03)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (9.09)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (5.48)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1-1"><p><sup>+</sup>Chi square test;</p></fn><fn id="TFN1-2"><p><sup>++</sup>t test;</p></fn><fn id="TFN1-3"><p>BCVA, best-corrected visual acuity; IOP, intraocular pressure; CCT, central corneal thickness; RNFL, retinal nerve fiber layer; C/D ratio, cup to disk ratio; MD, mean deviation; PSD, pattern standard deviation; SD, standard deviation; VFI: visual field index</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Statistical Analysis</title><p>Statistical analyses were performed using SAS Studio 3.5 (SAS Institute, Inc, Cary, North Carolina, USA), and <italic>p</italic>-value of &#x0003c;0.05 was considered statistically significant. The Kolmogorov-Smirnov test was used to verify the normal distribution of the study outcomes. Parametric and nonparametric statistics were used to compare different study outcomes between the study groups. Logistic regression analyses were performed on statistically significant study variables in the bivariate analysis to determine the association of 5-year glaucomatous progression with different factors.</p></sec></sec><sec sec-type="results"><title>R<sc>esults</sc></title><p>A total number of 365 eyes from 288 patients (323 eyes with concerning cup-to-disk ratio and 42 eyes with ocular hypertension) with mean age of 59.08 &#x000b1; 11.24 years old were included in this study. Overall, 55 (15.07%) eyes progressed to glaucoma within average &#x000b1; SD of 19.12 &#x000b1; 4.23 months (<xref rid="T1" ref-type="table">Table 1</xref>). <xref rid="T1" ref-type="table">Table 1</xref> shows bivariate analysis of different study variables between the study groups. Both study groups were statistically comparable with regard to age, sex, race, eye laterality, hypertension, diabetes mellitus, family history of glaucoma, fellow eye diagnosed with glaucoma, lens status, best-corrected visual acuity (BCVA), IOP, central corneal thickness, vertical cup-to-disk ratio, and cup-to-disk asymmetry (<italic>p</italic> &#x0003e; 0.05 for all; (<xref rid="T1" ref-type="table">Table 1</xref>). A total number of 48 (13.15%) eyes were on IOP-lowering medications at some point during the 5 years of follow-up (<xref rid="T1" ref-type="table">Table 1</xref>). There was no statistically significant difference between the study groups with regard to percentage of eyes on IOP-lowering medications (<italic>p</italic> = 0.70; <xref rid="T1" ref-type="table">Table 1</xref>) and mean number of medications (<italic>p</italic> = 0.09; (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p>Compared to the eyes without progression, eyes with progression to glaucoma had statistically significantly worse MD (<italic>p</italic> = 0.02), higher PSD (<italic>p</italic> &#x0003c; 0.01) and less VFI (<italic>p</italic> &#x0003c; 0.01) at baseline (<xref rid="T1" ref-type="table">Table 1</xref>). Among them, only PSD showed statistically significant positive association with 5-year glaucomatous progression on logistic regression analysis (<xref rid="T2" ref-type="table">Table 2</xref>). Both groups were statistically comparable with regard to percentage of eyes with MD worse or better than &#x02212;1dB (<italic>p</italic> = 0.12; <xref rid="T1" ref-type="table">Table 1</xref>). With regard to OCT parameters, there was no statistically significant difference between the study groups in terms of nasal and temporal RNFL thicknesses, cup volume, disk area and rim area at baseline (<italic>p</italic> &#x0003e; 0.05 for all; <xref rid="T1" ref-type="table">Table 1</xref>). The progressed group showed significantly thinner average, superior and inferior RNFL thicknesses (<italic>p</italic> &#x0003c; 0.01 for all; <xref rid="T1" ref-type="table">Table 1</xref>). While the progressed group had significantly more severe average, superior and inferior RNFL damages based on analysis of color grading scale (<italic>p</italic> &#x0003c; 0.01 for all), both study groups were statistically comparable with regard to severity of RNFL damage in nasal and temporal quadrants at baseline (<italic>p</italic> &#x0003e; 0.05 for all) (<xref rid="T1" ref-type="table">Table 1</xref>). Among those, the logistic regression analysis showed that only severe RNFL damage (i.e., red color) in the inferior quadrant was significantly associated with 5-year glaucomatous progression (<xref rid="T2" ref-type="table">Table 2</xref>). We found severe inferior RNFL damage (i.e., red color) has sensitivity, specificity, and positive and negative predictive values of 20.75%, 96.72%, 52.38%, and 87.28%, respectively.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Association of progression to glaucoma with different study outcomes: Logistic Regression Analysis</p></caption><table frame="hsides" rules="groups" cellpadding="10" cellspacing="0"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Coefficient &#x000b1; SE</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p-value</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>95% CI</italic>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline MD (dB)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.08 &#x000b1; 0.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.55</td><td align="center" valign="top" rowspan="1" colspan="1">0.70, 1.21</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline PSD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.77 &#x000b1; 1.16</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.64, 2.52</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline VFI</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.10 &#x000b1; 0.26</td><td align="center" valign="top" rowspan="1" colspan="1">0.69</td><td align="center" valign="top" rowspan="1" colspan="1">0.66, 1.86</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline inferior RNFL thickness (micron)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.01&#x000b1; 0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.76</td><td align="center" valign="top" rowspan="1" colspan="1">0.95, 1.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline superior RNFL thickness (micron)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.03 &#x000b1; 0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.93, 1.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline average RNFL thickness (micron)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.01 &#x000b1; 0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.85</td><td align="center" valign="top" rowspan="1" colspan="1">0.90, 1.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline average RNFL color</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Green</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.86 &#x000b1; 0.93</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">- 0.07, 0.97</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yellow</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.16 &#x000b1; 0.73</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">- 0.02, 1.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Red</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.14 &#x000b1; 0.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td><td align="center" valign="top" rowspan="1" colspan="1">- 0.01, 1.11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline inferior RNFL color</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Green</td><td align="center" valign="top" rowspan="1" colspan="1">1.26 &#x000b1; 1.16</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.36, 34.13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yellow</td><td align="center" valign="top" rowspan="1" colspan="1">1.34 &#x000b1; 1.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.28, 53.03</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Red</td><td align="center" valign="top" rowspan="1" colspan="1">3.62 &#x000b1; 1.35</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.03</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.64, 53.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Baseline superior RNFL color</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Green</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.76 &#x000b1; 0.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.08, 1.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yellow</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.11 &#x000b1; 0.84</td><td align="center" valign="top" rowspan="1" colspan="1">0.89</td><td align="center" valign="top" rowspan="1" colspan="1">0.21, 5.85</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Red</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.62 &#x000b1; 1.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.93</td><td align="center" valign="top" rowspan="1" colspan="1">0.17, 6.69</td></tr></tbody></table><table-wrap-foot><fn id="TFN2-1"><p>RNFL, retinal nerve fiber layer; MD, mean deviation; PSD, pattern standard deviation; SE, standard error; VFI, visual field index</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>D<sc>iscussion</sc></title><p>To successfully manage glaucoma, it is imperative to identify patients who are at higher risk of development and progression of glaucoma. This retrospective longitudinal study included 365 glaucoma suspect eyes of 288 patients. We investigated the association of several demographic, clinical, visual field and OCT variables with glaucomatous progression over a period of 5 years in a cohort of glaucoma suspect eyes.</p><p>Several studies including the Ocular Hypertension Treatment Study (OHTS)<sup><xref rid="B1" ref-type="bibr">1</xref></sup> and the European Glaucoma Prevention Study (EGPS)<sup><xref rid="B11" ref-type="bibr">11</xref></sup> have shown certain risk factors are predictive of the development of glaucoma. The OHTS has shown that baseline age, vertical and horizontal cup-to-disk ratio, PSD, and IOP were good predictors for the onset of primary open angle glaucoma (POAG) in ocular hypertensive patients.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> In addition, central corneal thickness, measured by pachymetry, was found to be a powerful predictor for the development of POAG.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> Furthermore, the OHTS has shown that the risk estimation for developing POAG in ocular hypertensive patients is equally accurate using IOP and central corneal thickness as measured, rather than applying a complicated adjustment formula to correct IOP for central corneal thickness.<sup><xref rid="B12" ref-type="bibr">12</xref></sup> Moreover, the OHTS has shown that optic disk hemorrhage is an independent predictive factor for development of POAG in patients with ocular hypertension.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> Additionally, the EGPS has found that baseline age, vertical cup-to-disk ratio, vertical cup-to-disk ratio asymmetry, and PSD were strong predictors of the onset of open angle glaucoma in patients with ocular hypertension. Similar to the OHTS, the EGPS found central corneal thickness was a powerful predictor of the development of open angle glaucoma.<sup><xref rid="B11" ref-type="bibr">11</xref></sup></p><p>In contrast to OHTS and EGPS, we did not find any significant association between age, central corneal thickness and cup-to-disk ratio, and 5-year glaucomatous progression. In our study, bivariate analysis showed that the glaucomatous progression group had significantly worse MD, higher PSD, and less VFI at baseline. However, only PSD showed statistically significant association with 5-year progression of glaucoma on the logistic regression analysis. We could not find any threshold for baseline MD that could significantly predict 5-year progression of glaucoma. For example, the study groups were not significantly different with regard to percentage of eyes with baseline MD worse or better than &#x02212;1dB (<xref rid="T1" ref-type="table">Table 1</xref>). The majority of glaucoma suspicious eyes in our study were based on optic nerve appearance. Therefore, findings of the OHTS and EGPS may not be comparable with our findings.</p><p>Structural and functional changes are useful indicators to detect glaucoma progression, but these changes often do not happen simultaneously over a period of time. However, both structural and functional progression will ultimately confirm the findings of the other modality during the course of follow-up. There is still controversy regarding whether structural changes precede functional loss as measured by perimetry.<sup><xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B23" ref-type="bibr">23</xref></sup> Although studies have different definitions for structural and functional progression, some studies have reported that structural changes precede functional changes in glaucoma progression.<sup><xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref></sup> The OHTS has shown that 35% of patients with visual field loss were without any sign of structural progression.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> Medeiros et al.<sup><xref rid="B25" ref-type="bibr">25</xref></sup> and Sehi et al.<sup><xref rid="B14" ref-type="bibr">14</xref></sup> have similarly reported that 34% and 37% of all glaucoma suspect individuals, respectively, developed visual field defects without structural progression. It is not quite clear why functional progression precedes structural progression in some patients and vice versa. In our study, we found eyes in the progressed group have significantly thinner baseline average, superior and inferior RNFL thicknesses in bivariate analysis. However, the logistic regression analysis did not show any significant association between average, superior, and inferior RNFL thicknesses and 5-year progression of glaucoma (<xref rid="T2" ref-type="table">Table 2</xref>). In bivariate analysis, we found that the progressed group had significantly more severe average, superior, and inferior RNFL damage based on the color grading scale at baseline. However, the logistic analysis showed only severe inferior RNFL damage was significantly associated with 5-year glaucomatous damage (<xref rid="T2" ref-type="table">Table 2</xref>). We found severe inferior RNFL damage (i.e., red color) has a very high specificity of 96.72% Taliantzis et al. have shown that segmental RNFL thickness on OCT examination constitutes an important indication of early functional changes, even if they are not still manifested on achromatic perimetry.<sup><xref rid="B24" ref-type="bibr">24</xref></sup> Lalezary et al. found that OCT RNFL measurements at baseline was an independent predictor for development of glaucomatous change in glaucoma suspect/preperimetric glaucoma and glaucomatous eyes. They reported that average and superior RNFL are significant predictors of subsequent visual field loss.<sup><xref rid="B26" ref-type="bibr">26</xref></sup> They found that for every 10 &#x003bc;m decrease in average RNFL there is an associated 38% higher chance for visual field progression; meanwhile, for every 10 &#x003bc;m thinning of superior RNFL, there is associated 20% higher chance of visual field progression.<sup><xref rid="B26" ref-type="bibr">26</xref></sup></p><p>Our study has potential limitations. Due to the retrospective nature of the study, eyes participated in this study were diagnosed at the discretion of the attending physician. This may make it difficult to determine the true 5-year progression of glaucoma. The majority of participated subjects in our study included glaucoma suspect eyes based on suspicious optic nerve appearance. This makes it difficult to compare our results with those of OHTS and EGPS where the majority of their subjects had glaucoma suspect eyes based on ocular hypertension. In addition, 83.33% of study population were African American which may make it difficult to generalize our results to other ethnicities.</p></sec><sec sec-type="conclusion"><title>C<sc>onclusion</sc></title><p>In conclusion, we found that severe baseline inferior RNFL damage and PSD were significantly associated with 5-year glaucomatous progression in glaucoma suspect eyes. We suggest that these eyes should be considered to be at a higher risk of glaucomatous progression. In addition, severe inferior RNFL damage has a specificity of 96.72%. Decisions on the implementation and extent of treatment for glaucoma suspect eyes can be difficult and need an understanding of important risk factors for development and progression of glaucoma. Further studies are warranted to determine the importance of different risk factors including genetic factors in glaucoma suspect eyes particularly those with suspicious optic nerve appearance. Currently, there is a lack of cohort studies determining the risk factors for glaucomatous progression in glaucoma suspects eyes based on optic nerve appearance.</p></sec><sec sec-type="orcid"><title>O<sc>rcid</sc></title><p><italic>Shibandri Das</italic>
<uri xlink:href="https://orcid.org/0000-0001-8327-9227" content-type="orcid">https://orcid.org/0000-0001-8327-9227</uri></p><p><italic>Faisal Ridha</italic>
<uri xlink:href="https://orcid.org/0000-0002-3983-2854" content-type="orcid">https://orcid.org/0000-0002-3983-2854</uri></p></sec></body><back><fn-group><fn id="fn1" fn-type="COI-statement"><p><bold>Source of support:</bold> Nil</p><p><bold>Conflict of interest:</bold> None</p></fn></fn-group><ref-list><title>R<sc>eferences</sc></title><ref id="B1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>MO</given-names></name><name><surname>Beiser</surname><given-names>JA</given-names></name><name><surname>Brandt</surname><given-names>JD</given-names></name><etal>et al.</etal></person-group><article-title>The ocular hypertensive treatment study: baseline factors that predict the onset of primary open-angle glaucoma.</article-title><source>Arch Ophthalmol</source><year>2002</year><volume>120</volume><issue>6</issue><fpage>714</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1001/archopht.120.6.714</pub-id><pub-id pub-id-type="pmid">12049575</pub-id></element-citation></ref><ref id="B2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tielsch</surname><given-names>JM</given-names></name><name><surname>Katz</surname><given-names>J</given-names></name><name><surname>Sommer</surname><given-names>A</given-names></name><etal>et al.</etal></person-group><article-title>Family history and risk of primary open-angle glaucoma: the Baltimore eye study.</article-title><source>Arch Ophthalmol</source><year>1994</year><volume>112</volume><issue>1</issue><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1001/archopht.1994.01090130079022</pub-id><pub-id pub-id-type="pmid">8285897</pub-id></element-citation></ref><ref id="B3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>W</given-names></name><name><surname>Chey</surname><given-names>T</given-names></name><etal>et al.</etal></person-group><article-title>Open angle glaucoma and diabetes.</article-title><source>Ophthalmology</source><year>1997</year><volume>104</volume><issue>4</issue><fpage>712</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1016/s0161-6420(97)30247-4</pub-id><pub-id pub-id-type="pmid">9111268</pub-id></element-citation></ref><ref id="B4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>AJ</given-names></name><name><surname>Rochtchina</surname><given-names>E</given-names></name><etal>et al.</etal></person-group><article-title>Open-angle glaucoma and systemic hypertension: the Blue Mountains eye study.</article-title><source>J Glaucoma</source><year>2004</year><volume>13</volume><issue>4</issue><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1097/00061198-200408000-00010</pub-id><pub-id pub-id-type="pmid">15226661</pub-id></element-citation></ref><ref id="B5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drance</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>DR</given-names></name><name><surname>Schulzer</surname><given-names>M</given-names></name><etal>et al.</etal></person-group><article-title>Risk factors for progression of visual field abnormalities in normal- tension glaucoma.</article-title><source>Am J Ophthalmol</source><year>2001</year><volume>131</volume><issue>6</issue><fpage>699</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/s0002-9394(01)00964-3</pub-id><pub-id pub-id-type="pmid">11384564</pub-id></element-citation></ref><ref id="B6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Hourihan</surname><given-names>F</given-names></name><name><surname>Sandbach</surname><given-names>J</given-names></name><etal>et al.</etal></person-group><article-title>The relationship between glaucoma and myopia: the Blue Mountains eye study.</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><issue>10</issue><fpage>2010</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1016/s0161-6420(99)90416-5</pub-id><pub-id pub-id-type="pmid">10519600</pub-id></element-citation></ref><ref id="B7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landers</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>K</given-names></name><name><surname>Sarkies</surname><given-names>N</given-names></name><etal>et al.</etal></person-group><article-title>A 20 year follow-up study of trabeculectomy: risk factors and outcomes.</article-title><source>Ophthalmology</source><year>2012</year><volume>119</volume><issue>4</issue><fpage>694</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2011.09.043</pub-id><pub-id pub-id-type="pmid">22196977</pub-id></element-citation></ref><ref id="B8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kass</surname><given-names>MA</given-names></name><name><surname>Heuer</surname><given-names>DK</given-names></name><name><surname>Higginbotham</surname><given-names>EJ</given-names></name><etal>et al.</etal></person-group><article-title>The ocular hypertension treatment study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.</article-title><source>Arch Ophthalmol</source><year>2002</year><volume>120</volume><issue>6</issue><fpage>701</fpage><lpage>713</lpage><comment>discussion 829&#x02013;830.</comment><pub-id pub-id-type="doi">10.1001/archopht.120.6.701</pub-id><pub-id pub-id-type="pmid">12049574</pub-id></element-citation></ref><ref id="B9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moyer</surname><given-names>VA</given-names></name><collab>U.S. Preventive Services Task Force.</collab></person-group><article-title>Screening for glaucoma: U.S. Preventive Services Task Force Recommendation Statement.</article-title><source>Ann Intern Med</source><year>2013</year><volume>159</volume><issue>7</issue><fpage>484</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-159-6-201309170-00686</pub-id><pub-id pub-id-type="pmid">24325017</pub-id></element-citation></ref><ref id="B10"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>DR</given-names></name><name><surname>Patella</surname><given-names>VM</given-names></name></person-group><part-title>Automated static perimetry.</part-title><publisher-loc>St. Louis</publisher-loc><publisher-name>Mosby</publisher-name><year>1999</year></element-citation></ref><ref id="B11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miglior</surname><given-names>S</given-names></name><name><surname>Pfeiffer</surname><given-names>N</given-names></name><name><surname>Torri</surname><given-names>V</given-names></name><etal>et al.</etal></person-group><article-title>Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study.</article-title><source>Ophthalmology</source><year>2007</year><volume>114</volume><issue>1</issue><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2006.05.075</pub-id><pub-id pub-id-type="pmid">17070596</pub-id></element-citation></ref><ref id="B12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>JD</given-names></name><name><surname>Gordon</surname><given-names>MO</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><etal>et al.</etal></person-group><article-title>Ocular hypertension treatment study group. Adjusting intraocular pressure for central corneal thickness does not improve prediction models for primary open-angle glaucoma.</article-title><source>Ophthalmology</source><year>2012</year><volume>119</volume><issue>3</issue><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2011.03.018</pub-id><pub-id pub-id-type="pmid">21705084</pub-id></element-citation></ref><ref id="B13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budenz</surname><given-names>DL</given-names></name><name><surname>Huecker</surname><given-names>JB</given-names></name><name><surname>Gedde</surname><given-names>SJ</given-names></name><etal>et al.</etal></person-group><article-title>Ocular hypertension treatment study group. Thirteen-year follow-up of optic disk hemorrhages in the Ocular Hypertension Treatment Study.</article-title><source>Am J Ophthalmol</source><year>2017</year><volume>174</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2016.10.023</pub-id><pub-id pub-id-type="pmid">27832941</pub-id></element-citation></ref><ref id="B14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Greenfield</surname><given-names>DS</given-names></name><etal>et al.</etal></person-group><article-title>Advanced Imaging for Glaucoma Study Group. Retinal nerve fiber layer atrophy is associated with visual field loss over time in glaucoma suspect and glaucomatous eyes.</article-title><source>Am J Ophthalmol</source><year>2013</year><volume>155</volume><issue>1</issue><fpage>73</fpage><lpage>82.e1</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2012.07.005</pub-id><pub-id pub-id-type="pmid">23036570</pub-id></element-citation></ref><ref id="B15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artes</surname><given-names>PH</given-names></name><name><surname>Chauhan</surname><given-names>BC</given-names></name></person-group><article-title>Longitudinal changes in the visual field and optic disk in glaucoma.</article-title><source>Prog Retin Eye Res</source><year>2005</year><volume>24</volume><issue>3</issue><fpage>333</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2004.10.002</pub-id><pub-id pub-id-type="pmid">15708832</pub-id></element-citation></ref><ref id="B16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenfield</surname><given-names>DS</given-names></name></person-group><article-title>Optic nerve and retinal nerve fiber layer analyzers in glaucoma.</article-title><source>Curr Opin Ophthalmol</source><year>2002</year><volume>13</volume><issue>2</issue><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1097/00055735-200204000-00003</pub-id><pub-id pub-id-type="pmid">11880718</pub-id></element-citation></ref><ref id="B17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Crabb</surname><given-names>DP</given-names></name><name><surname>Fredette</surname><given-names>MJ</given-names></name><etal>et al.</etal></person-group><article-title>Quantifying discordance between structure and function measurements in the clinical assessment of glaucoma.</article-title><source>Arch Ophthalmol</source><year>2011</year><volume>129</volume><issue>9</issue><fpage>1167</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1001/archophthalmol.2011.112</pub-id><pub-id pub-id-type="pmid">21555599</pub-id></element-citation></ref><ref id="B18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Crabb</surname><given-names>DP</given-names></name><name><surname>Schlottmann</surname><given-names>PG</given-names></name><etal>et al.</etal></person-group><article-title>Predicting visual function from the measurements of retinal nerve fiber layer structure.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2010</year><volume>51</volume><issue>11</issue><fpage>5657</fpage><lpage>5666</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-5239</pub-id><pub-id pub-id-type="pmid">20505207</pub-id></element-citation></ref><ref id="B19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsini</surname><given-names>B</given-names></name><name><surname>Marangoni</surname><given-names>D</given-names></name><name><surname>Salgarello</surname><given-names>T</given-names></name><etal>et al.</etal></person-group><article-title>Structure-function relationship in ocular hypertension and glaucoma: interindividual and interocular analysis by OCT and pattern ERG.</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2008</year><volume>246</volume><issue>8</issue><fpage>1153</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1007/s00417-008-0808-5</pub-id><pub-id pub-id-type="pmid">18386035</pub-id></element-citation></ref><ref id="B20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strouthidis</surname><given-names>NG</given-names></name><name><surname>Vinciotti</surname><given-names>V</given-names></name><name><surname>Tucker</surname><given-names>AJ</given-names></name><etal>et al.</etal></person-group><article-title>Structure and function in glaucoma: the relationship between a functional visual field map and an anatomic retinal map.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><issue>12</issue><fpage>5356</fpage><lpage>5362</lpage><pub-id pub-id-type="doi">10.1167/iovs.05-1660</pub-id><pub-id pub-id-type="pmid">17122124</pub-id></element-citation></ref><ref id="B21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harwerth</surname><given-names>RS</given-names></name><name><surname>Quigley</surname><given-names>HA</given-names></name></person-group><article-title>Visual field defects and retinal ganglion cell losses in patients with glaucoma.</article-title><source>Arch Ophthalmol</source><year>2006</year><volume>124</volume><issue>6</issue><fpage>853</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1001/archopht.124.6.853</pub-id><pub-id pub-id-type="pmid">16769839</pub-id></element-citation></ref><ref id="B22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>Sample</surname><given-names>PA</given-names></name><name><surname>Zangwill</surname><given-names>LM</given-names></name><etal>et al.</etal></person-group><article-title>Structure and function evaluation (SAFE): II. Comparison of optic disk and visual field characteristics.</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>135</volume><issue>2</issue><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/s0002-9394(02)01930-x</pub-id><pub-id pub-id-type="pmid">12566017</pub-id></element-citation></ref><ref id="B23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>Cioffi</surname><given-names>GA</given-names></name><name><surname>Liebmann</surname><given-names>JR</given-names></name><etal>et al.</etal></person-group><article-title>The relationship between structural and functional alterations in glaucoma: a review.</article-title><source>Semin Ophthalmol</source><year>2000</year><volume>15</volume><issue>4</issue><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.3109/08820530009037873</pub-id><pub-id pub-id-type="pmid">17585436</pub-id></element-citation></ref><ref id="B24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taliantzis</surname><given-names>S</given-names></name><name><surname>Papaconstantinou</surname><given-names>D</given-names></name><name><surname>Koutsandrea</surname><given-names>C</given-names></name><etal>et al.</etal></person-group><article-title>Comparative studies of RNFL thickness measured by OCT with global index of visual fields in patients with ocular hypertension and early open angle glaucoma.</article-title><source>Clin Ophthalmol</source><year>2009</year><volume>3</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.2147/opth.s6150</pub-id><pub-id pub-id-type="pmid">19668593</pub-id></element-citation></ref><ref id="B25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medeiros</surname><given-names>FA</given-names></name><name><surname>Alencar</surname><given-names>LM</given-names></name><name><surname>Zangwill</surname><given-names>LM</given-names></name><etal>et al.</etal></person-group><article-title>Prediction of functional loss in glaucoma from progressive optic disk damage.</article-title><source>Arch Ophthalmol</source><year>2009</year><volume>127</volume><issue>10</issue><fpage>1250</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1001/archophthalmol.2009.276</pub-id><pub-id pub-id-type="pmid">19822839</pub-id></element-citation></ref><ref id="B26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalezary</surname><given-names>M</given-names></name><name><surname>Medeiros</surname><given-names>FA</given-names></name><name><surname>Weinreb</surname><given-names>RN</given-names></name><etal>et al.</etal></person-group><article-title>Baseline optical coherence tomography predicts the development of glaucomatous change in glaucoma suspects.</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>142</volume><issue>4</issue><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2006.05.004</pub-id><pub-id pub-id-type="pmid">17011848</pub-id></element-citation></ref></ref-list></back></article>
